2024
DOI: 10.1007/s10006-024-01245-y
|View full text |Cite
|
Sign up to set email alerts
|

Denosumab as treatment of central giant cell granuloma of the jaws. a scoping review

Constanza Godoy Latorre,
Camila Nahmías Atalah,
Maureen Marshall Baburizza
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 36 publications
0
1
0
Order By: Relevance
“…It acts by binding to and inhibiting the receptor activator of the nuclear factor kappa B ligand (RANKL), resulting in a loss of osteoclasts. In addition, promising results have been reported regarding the off-label use of denosumab in other giant cell-rich tumors, including aneurysmal bone cyst (ABC) [27,28] and central giant cell granuloma [29,30]. Therefore, it is hypothesized that the use of denosumab may also be beneficial and effective in selected cases of KPGCT.…”
Section: Advanced/metastatic Diseasementioning
confidence: 99%
“…It acts by binding to and inhibiting the receptor activator of the nuclear factor kappa B ligand (RANKL), resulting in a loss of osteoclasts. In addition, promising results have been reported regarding the off-label use of denosumab in other giant cell-rich tumors, including aneurysmal bone cyst (ABC) [27,28] and central giant cell granuloma [29,30]. Therefore, it is hypothesized that the use of denosumab may also be beneficial and effective in selected cases of KPGCT.…”
Section: Advanced/metastatic Diseasementioning
confidence: 99%